-1 	|BT| (NP (NP (NN BACKGROUND/AIMS)) (: :) (NP (NP (JJ Several) (NN study)) (VP (VBD reported) (NP (NP (NP (NP (NP (NN efficacy) (NN combination) (NN therapy) (NN interferon)) (PRN (-LRB- -LRB-) (NP (NN IFN)) (-RRB- -RRB-))) (NN alpha) (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 617:D12.644.276.374.440 618:E02.186|ES| 10:1 14:1 19:1 104:1 130:1 131:1 303:1 304:1 441:1 530:1 993:1 1836:1 2302:1 2303:1 2304:1 2305:1 2306:1 2307:1 2308:1
-1 	|BT| (NP (NP (NP (NN BACKGROUND/AIMS)) (: :) (NP (NP (DT The) (NN success) (NN sorafenib) (NN treatment)) (VP (VBD advanced) (SBAR (S (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (VP (VBD focused) (NP (NN interest) (NN role) (NN Ras) (NN signaling) (NN malignancy))))))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 15:F01.829.316.616 52:E02 69:G02.111.087.800 104:C04.557.470.200.025.255|ES| 10:1 14:1 19:1 31:1 49:1 104:1 195:1 303:1 304:1 441:1 546:1 691:1 997:1 1775:1 2063:1 2302:1 2309:1 2310:1 2311:1
-1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (NP (NNP Magnolol) (, ,) (NN plant) (NN lignan)) (NP (VBN isolated) (NN bark) (NN seed) (NN cone) (NN Magnolia) (NN officinalis)) (, ,) (VP (VBN shown) (NP (JJ chemopreventive) (NN effect) (JJ chemically-induced) (NN skin) (NN cancer) (NN development))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 328:B01.650 619:D02.455.426.559.847.117.159.205 620:B01.650.940.800.575.100.680.500 621:D02.455.426.559.389.140.450 622:A08.675.650.850.625.670.100 623:A08.186.211.730.885.287.500 624:D27.505.696.706.018 625:A06.407.071.140 626:A05.810.453.324 627:A18.024.500.750|ES| 2:1 18:1 19:1 35:1 75:1 104:1 237:1 1046:1 1098:1 1653:1 1946:1 2233:1 2312:1 2313:1 2314:1 2315:1 2316:1 2317:1 2318:1 2319:1
-1 	|BT| (NP (NP (NP (NNP Brucine) (NN alkaloid) (VBN derived) (NN seed) (NNS Strychnos)) (NP (JJ nux-vomica) (NNP Linn)))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 629:E02.190.488 630:Z01.252.474.164 631:D03.132|ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 1721:1 2315:1 2320:1 2321:1 2322:1 2323:1 2324:1 2325:1 2326:1 2327:1 2328:1
-1 	|BT| (S (S (NP (NP (NP (JJ Caffeic) (NN acid) (NN phenethyl) (NN ester)) (PRN (-LRB- -LRB-) (NP (NN CAPE)) (-RRB- -RRB-))) (, ,) (NP (JJ natural) (NN component)) (NP (NN propolis)) (, ,)) (VP (VBP show) (S (NP (JJ anticarcinogenic) (NN property)) (VP (NP (VBN modified) (JJ resistant) (NN hepatocyte) (NN model)) (S (NP (VBN administered) (NN initiation) (NN promotion) (NN hepatocarcinogenesis) (NN process))))))) (: ;) (RB however) (, ,) (NP (NP (NN information) (NN mechanism)) (VP (VBG underlying) (S (NP (NN chemoprotection)) (ADJP (VBN limited)))))) |ET| |BS|262:A11.436.348 632:D05.750.078.840.762|ES| 2:1 10:1 14:1 19:1 72:1 162:1 217:1 333:1 427:1 429:1 435:1 637:1 638:1 841:1 900:1 1021:1 1275:1 1387:1 1909:1 2131:1 2329:1 2330:1 2331:1 2332:1 2333:1 2334:1 2335:1 2336:1 2337:1 2338:1 2339:1
-1 	|BT| (S (NP (NP (NP (JJ Epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN tyrosine) (NN kinase) (NN inhibitor) (NN erlotinib)) (VP (VBP show) (SBAR (S (NP (JJ potent) (NP (NP (NN antitumor) (NN activity) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (NN cell) (NN line)) (VP (VBD approved) (NP (NNP Food) (NNP Drug) (NNP Administration) (JJ second) (JJ third) (NN line) (NN treatment) (NN NSCLC))))))) |ET| |BS|52:E02 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 113:C04.697.650 633:I01.409.418.750.600.650.760 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 22:1 94:1 102:1 185:1 186:1 187:1 264:1 327:1 328:1 329:1 380:1 399:1 429:1 470:1 546:1 2244:1 2340:1 2341:1 2342:1 2343:1 2344:1 2345:1 2346:1 2347:1 2348:1
-1 	|BT| (NP (NN Hepatocyte) (NP (NP (CD I) (NN kappaB) (NN kinase) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN IKK) (NN beta)) (-RRB- -RRB-))) (VBZ inhibits) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG suppressing) (NP (NP (NP (NN accumulation) (JJ reactive) (NN oxygen) (NN specie)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))) (NN liver) (NN damage)))) (, ,) (SBAR (IN whereas) (S (NP (NN JNK1) (NN activation)) (VP (VBZ promotes) (NP (NP (NN ROS) (NN accumulation)) (, ,) (NP (NN liver) (NN damage)) (, ,) (NP (NN carcinogenesis))))))) |ET| |BS|33:C04.697.098 122:C14.280.383 242:A03.620 262:A11.436.348 635:D08.811.913.696.620.682.700.494 636:D01.339.431|ES| 2:1 10:1 14:1 19:1 207:1 225:1 298:1 372:1 470:1 615:1 836:1 900:1 1848:1 1972:1 2120:1 2250:1 2349:1 2350:1 2351:1 2352:1 2353:1 2354:1 2355:1 2356:1 2357:1
-1 	|BT| (NP (NP (NN PURPOSE)) (: :) (S (NP (JJ Recent) (NN study)) (VP (VBD revealed) (S (NP (NP (JJ branched-chain) (NN amino) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN BCAA)) (-RRB- -RRB-))) (VP (VB reduce) (NP (NP (NP (NN development) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN patient) (NN obesity) (NN hepatitis) (NN C) (NN virus) (NN infection) (S (VP (VBG improving) (NP (NP (NN insulin) (NN resistance)) (PRN (-LRB- -LRB-) (NP (NN IR)) (-RRB- -RRB-))))))))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 550:B04.450.410 564:C18.654.726.500 637:D06.472.699.587.200.500.625 638:C02.440.440 639:D12.125.070|ES| 10:1 14:1 19:1 35:1 104:1 120:1 131:1 275:1 303:1 304:1 441:1 687:1 1094:1 1275:1 1422:1 1955:1 2010:1 2048:1 2189:1 2358:1 2359:1 2360:1 2361:1 2362:1 2363:1 2364:1 2365:1
-1 	|BT| (NP (NP (NP (NN Tamoxifen) (JJ non-steroidal) (JJ anti-estrogenic) (NN drug)) (NP (ADJP (RB widely) (JJ used)) (NN treatment) (NN prevention) (NN breast) (NN cancer) (NN woman))) (: ;) (FRAG (ADVP (RB however)) (, ,) (NP (NP (NN evidence) (NN tamoxifen) (JJ hepatocarcinogenic) (NN rat)) (, ,) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 67:D26 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 640:D02.455.426.559.389.150.700.900 641:D27.505.696.399.472.277.540 642:M01.975|ES| 2:1 18:1 19:1 23:1 38:1 52:1 191:1 217:1 476:1 546:1 849:1 1387:1 1474:1 2366:1 2367:1 2368:1 2369:1 2370:1 2371:1 2372:1
-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN inflexinol)) (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN growth)) (PP (IN via) (NP (NP (NN induction)) (NP (NP (JJ apoptotic) (NN cell) (NN death) (NN inactivation) (NN NF-kappaB)) (NP (NP (JJ direct) (NN modification) (NN cysteine) (NN residue)) (NP (NN p50) (NN subunit) (NN NF-kappaB)))))))))))) |ET| |BS|38:Z01.058.290.120.180 39:G04.299.139.160 40:Z01.542.248.700 45:G07.700.320.249 46:A03.556.124.526.356 122:C14.280.383 210:D12.776.260.600 583:D12.776.813 643:D02.886.030.230|ES| 18:1 19:1 94:1 101:1 102:1 113:1 411:1 596:1 615:1 714:1 736:1 792:1 796:1 1314:1 1891:1 2110:1 2223:1 2373:1 2374:1 2375:1 2376:1 2377:1
-1 	|BT| (S (NP (DT This) (NN research)) (VP (VBZ provides) (NP (NN evidence) (NN tea)) (, ,) (NP (ADVP (RB particularly)) (NP (VBN administered) (NN combination) (NN sulindac)) (, ,) (NP (PP (ADJP (RB highly) (JJ effective)) (S (VP (VBG inhibiting) (NP (NP (NP (JJ intestinal) (NN neoplasia) (NN male) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN min)) (-RRB- -RRB-))) (NN mouse)) (PP (IN via) (NP (JJ direct) (JJ indirect) (NN effect) (NN beta-catenin/APC) (NN pathway)))))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 102:C04.588.274.476.411 122:C14.280.383 251:D02.455.426.559.847.486.875 644:H01.770.644 645:H01.770.644|ES| 2:1 10:1 14:1 19:1 38:1 52:1 75:1 109:1 280:1 383:1 530:1 596:1 626:1 640:1 807:1 815:1 869:1 880:1 1402:1 1639:1 1891:1 2336:1 2378:1 2379:1 2380:1 2381:1 2382:1 2383:1
-1 	|BT| (S (NP (NP (NNP UNLABELLED)) (: :) (S (NP (JJ Epidemiological) (NNS data)) (VP (VBP associate) (NP (NP (NN coffee) (NN consumption)) (NP (JJR lower) (NN prevalence) (JJ chronic) (NN liver) (NN disease))) (VP (VBD reduced) (NP (NP (NN risk) (JJ elevated) (NN liver) (NN enzyme) (NN level)) (PRN (-LRB- -LRB-) (NP (NN gamma) (NN glutamyl) (NN transpeptidase) (NN alanine) (NN aminotransferase)) (-RRB- -RRB-)))))) (, ,)) (VP (VBD advanced) (NP (NP (NN liver) (NN disease) (NN complication)) (, ,) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|60:E05.318.308.985.525.750 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 646:D08.811.913.477.700.100 647:D08.811.913.477.700.347 648:D08.811.913.050.200.500 649:E01.370.225.124.200 650:C06.552 651:H02.403.720.500 652:D20.215.784.249|ES| 2:1 10:1 14:1 19:1 104:1 117:1 171:1 179:1 249:1 303:1 304:1 452:1 756:1 793:1 836:1 997:1 998:1 1790:1 2266:1 2384:1 2385:1 2386:1 2387:1 2388:1 2389:1 2390:1 2391:1 2392:1 2393:1 2394:1
-1 	|BT| (S (NP (NN 5-aza-dC) (NN treatment)) (ADVP (RB markedly)) (VP (VBD decreased) (NP (NP (NN atherosclerosis) (NN development) (NN Ldlr)) (-LRB- -LRB-) (PRN (: -) (: /) (: -)) (-RRB- -RRB-) (NN mouse)) (NP (PP (IN without) (NP (NN change) (NN body) (NN weight))) (, ,) (NP (NN plasma) (NN lipid) (NN profile)) (, ,) (NP (NN macrophage) (NN cholesterol) (NN level) (NN plaque) (NN lipid) (NN content))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 511:C14.907.137.126.307 513:C14.907.137.126 558:C23.300.821 653:C23.888.144 654:D02.145.150 655:D04.808.247.222.284 656:C07.793.208.377 657:A12.207.152.693 658:A11.329.372 659:D10|ES| 2:1 10:1 14:1 19:1 35:1 45:1 52:1 200:1 202:1 249:1 546:1 1195:1 1711:1 1794:1 1804:1 1981:1 2395:1 2396:1 2397:1 2398:1 2399:1 2400:1 2401:1 2402:1 2403:1
-1 	|BT| (NP (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (CD one) (JJ common) (JJ chemotherapeutic) (NN agent)) (VP (VBN used) (NP (NP (NN treatment) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 10:1 14:1 19:1 303:1 304:1 441:1 476:1 546:1 655:1 728:1 1010:1 1762:1 2308:1 2404:1
-1 	|BT| (NP (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NP (NP (CD one) (ADJP (RB commonly) (VBN used)) (JJ chemotherapeutic) (NN agent) (NN colon) (NN cancer) (NN treatment)) (, ,) (NP (JJ narrow) (JJ therapeutic) (NN index) (JJ limited) (NN toxicity))))) |ET| |BS|46:A03.556.124.526.356 52:E02 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 2:1 10:1 14:1 15:1 18:1 19:1 113:1 476:1 541:1 546:1 721:1 728:1 1010:1 1762:1 2131:1 2308:1 2404:1 2405:1 2406:1
-1 	|BT| (S (NP (NP (NP (NN 5-Fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ common) (JJ chemotherapeutic) (NN agent)) (VP (VBN used) (NP (NP (NP (NN treatment) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (, ,) (NP (JJ inadequate) (NN response) (NN rate)) (: ;) (VP (VBG highlighting) (NP (NN need) (NN novel))))))) (VP (VBD improved) (NP (NN treatment) (NNS regimen) (NN patient)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 52:E02 259:D12.776.395.240.150.500 284:N03.349.380.420 532:E02.183 560:D03.383.742.698.875.404 660:D27.505.954.248|ES| 2:1 10:1 14:1 17:1 18:1 19:1 41:1 120:1 217:1 245:1 476:1 494:1 546:1 655:1 728:1 891:1 1762:1 1881:1 2308:1 2404:1 2407:1 2408:1 2409:1 2410:1
-1 	|BT| (S (NP (NNP Administration) (NNP SP600125) (NN acetaminophen)) (VP (VBD protected) (NP (NP (NP (NN Jnk)) (PRN (-LRB- -LRB-) (NP (NN Deltahepa)) (-RRB- -RRB-))) (NN control) (NN mouse) (NN liver) (NN injury)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 661:D02.065.199.092.040|ES| 10:1 14:1 19:1 52:1 289:1 836:1 2346:1 2411:1 2412:1 2413:1 2414:1 2415:1 2416:1
-1 	|BT| (S (NP (NNP Administration) (NN HMGB1) (NN release) (NN inhibitor) (NN ethyl) (NN pyruvate)) (, ,) (VP (VBP affect) (NP (NP (JJ p53-mediated) (JJ hepatic) (NN apoptosis)) (, ,) (VP (ADVP (RB substantially)) (VBD prevented) (NP (JJ carcinogen-induced) (NN cirrhosis) (NN tumorigenesis) (NN rat) (NN liver)))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 279:D27.888.569.100 357:C06.552.630 433:F01.470.047 585:D12.644.276.087.371 589:E02.204.125 662:C23.550.355|ES| 2:1 19:1 78:1 89:1 380:1 836:1 838:1 849:1 1199:1 1486:1 1944:1 2164:1 2165:1 2346:1 2417:1 2418:1 2419:1 2420:1 2421:1
-1 	|BT| (S (NP (NNP Aliskiren)) (VP (VBZ attenuates) (NP (NN steatohepatitis) (NN increase) (NN turnover) (JJ hepatic) (JJ fat) (NN mouse) (NN fed) (NN methionine) (NN choline) (JJ deficient) (NN diet)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676 665:N04.452.677.680|ES| 19:1 40:1 52:1 838:1 1504:1 1791:1 2050:1 2191:1 2422:1 2423:1 2424:1 2425:1 2426:1 2427:1
-1 	|BT| (S (NP (DT All) (NN result)) (VP (VBD revealed) (NP (NP (NN pterostilbene) (JJ effective) (NN antitumor) (NN agent)) (NP (RB well) (NP (JJ inhibitory) (NN effect) (NN down-regulation) (JJ inflammatory) (NN iNOS) (NN COX-2) (NN gene)) (NN expression) (NN up-regulation) (NN apoptosis) (NN mouse) (NN colon))) (, ,) (S (VP (VBG suggesting) (NP (NP (NP (NN pterostilbene)) (JJ novel) (JJ functional) (NN agent)) (ADJP (JJ capable) (S (VP (VBG preventing) (NP (JJ inflammation-associated) (NN colon) (NN tumorigenesis)))))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 39:G04.299.139.160 46:A03.556.124.526.356 53:C06.405.205.265 85:G02.111.087.225 155:G05.355.310 249:G05.355.315.800 259:D12.776.395.240.150.500 339:G02.111.087.880 660:D27.505.954.248|ES| 2:1 9:1 19:1 52:1 67:1 75:1 76:1 78:1 89:1 101:1 113:1 115:1 257:1 275:1 415:1 728:1 787:1 891:1 896:1 965:1 1009:1 1639:1 1849:1 1937:1 2244:1 2428:1 2429:1 2430:1 2431:1
-1 	|BT| (S (NP (NP (NNP Alternol)) (, ,) (NP (JJ natural) (NN compound)) (, ,)) (VP (VBZ exerts) (NP (NP (JJ anti-tumour) (NN effect) (NN osteosarcoma)) (VP (VBG modulating) (NP (NN STAT3) (NN ROS/MAPK) (NN signalling) (NN pathway)))))) |ET| |BS|12:Z01.542.049 38:Z01.058.290.120.180 40:Z01.542.248.700 82:D12.644.360.024.342.300 447:C04.557.450.565.575.650 666:G02.111.087.800.560|ES| 2:1 19:1 75:1 251:1 383:1 1562:1 1977:1 2333:1 2432:1 2433:1 2434:1 2435:1 2436:1 2437:1
-1 	|BT| (S (NP (JJ Anthocyanin-containing) (JJ purple-fleshed) (NN potato)) (VP (VBP suppress) (NP (NP (NN colon) (NN tumorigenesis)) (PP (IN via) (NP (NN elimination) (NN colon) (NN cancer) (NN stem) (NN cell)))))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 308:A11.872 667:B01.650.940.800.575.100.905.725.777 668:B01.650.940.800.575.100.905.725.777 669:D03.383.663.283.266.450.087|ES| 18:1 19:1 78:1 94:1 113:1 156:1 596:1 1106:1 2438:1 2439:1 2440:1 2441:1
-1 	|BT| (FRAG (NP (NP (JJ Anti-tumor) (NN effect)) (VBN pegylated) (NN interferon) (NN rat) (NN hepatocarcinogenesis) (NN model))) |ET| |BS|8:C04 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 617:D12.644.276.374.440|ES| 19:1 72:1 75:1 849:1 900:1 2305:1 2442:1 2443:1
-1 	|BT| (SINV (PP (IN As) (NP (NN wogonin) (ADJP (JJ effective) (ADVP (FW vitro) (FW vivo))))) (, ,) (NP (JJ novel) (S (VP (VBG finding) (S (NP (JJ open) (NN possibility) (NN wogonin) (JJ effective) (ADJP (ADJP (JJ therapeutic)) (CC and/or) (ADJP (JJ chemopreventive))) (NN agent)) (ADJP (JJ ER-positive))) (: -) (NP (NP (JJ negative) (NN breast) (NN cancer)) (, ,) (NP (RB particularly) (JJ aggressive) (JJ hormonal) (JJ therapy-resistant) (JJ ER-negative) (NN type))))))) |ET| |BS|52:E02 162:F01.145.126.125 259:D12.776.395.240.150.500|ES| 2:1 18:1 19:1 23:1 149:1 168:1 216:1 343:1 378:1 538:1 541:1 543:1 728:1 891:1 927:1 1045:1 1639:1 1654:1 1946:1 2380:1 2444:1 2445:1 2446:1 2447:1 2448:1
-1 	|BT| (NP (NP (NP (NP (NN Aspirin)) (PRN (-LRB- -LSB-) (NP (NP (JJ acetylsalicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN ASA)) (-RRB- -RRB-))) (-RRB- -RSB-))) (VP (VBN shown) (VP (VBP prevent) (NP (NN CRC))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ epigenetic) (NN mechanism) (NN action)) (VP (VBP remain) (ADJP (JJ unknown))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 670:D02.455.426.559.389.657.410.595.176 671:G05.355.315.203|ES| 2:1 10:1 14:1 19:1 162:1 217:1 237:1 245:1 733:1 1275:1 1373:1 1378:1 1387:1 1603:1 2013:1 2181:1 2182:1 2449:1 2450:1 2451:1
-1 	|BT| (S (NP (NN AZD6244) (NN doxorubicin)) (VP (VBP induce) (NP (NN growth) (NN suppression) (NN apoptosis) (NN mouse) (NN model) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 45:G07.700.320.249 104:C04.557.470.200.025.255 136:D02.455.426.559.847.562.050.200.175|ES| 19:1 52:1 72:1 89:1 102:1 243:1 303:1 304:1 599:1 2452:1 2453:1
-1 	|BT| (NP (NP (NP (NN Beta-ionone)) (, ,) (NP (JJ end-ring) (NN analogue) (NN beta-carotenoid)) (, ,) (NP (NN constituent) (NN vegetable) (NN fruit)) (, ,)) (NP (VBN analyzed) (NN colon) (NN cancer) (NN chemoprevention) (NN treatment))) |ET| |BS|12:Z01.542.049 52:E02 253:E02.319.162 672:D02.455.326.271.665.202 673:A18.024.500 674:B01.650.510.956|ES| 2:1 18:1 19:1 113:1 546:1 870:1 1168:1 1380:1 2454:1 2455:1 2456:1 2457:1 2458:1 2459:1
-1 	|BT| (S (NP (NNP Bortezomib)) (ADVP (RB also)) (VP (VBD prevented) (SBAR (S (NP (NN activation) (JJ hepatic) (JJ stellate) (NN cell)) (VP (VBD inhibited) (NP (NN liver) (NN fibrosis) (NN DEN/CDAA) (NN model))))))) |ET| |BS|122:C14.280.383 675:D01.029.260.110.500 676:C06.552.630 677:A11.561|ES| 5:1 19:1 72:1 94:1 225:1 365:1 836:1 838:1 949:1 1944:1 2460:1 2461:1 2462:1
-1 	|BT| (S (NP (NN Bortezomib)) (VP (VBZ induces) (SBAR (S (NP (NP (JJ tumor-specific) (NN cell) (NN death)) (NN growth) (NN inhibition) (JJ hepatocellular) (NN carcinoma)) (VP (VBZ improves) (NP (NN liver) (NN fibrosis))))))) |ET| |BS|8:C04 43:F01.145.544 45:G07.700.320.249 104:C04.557.470.200.025.255 134:G04.299.139 675:D01.029.260.110.500 676:C06.552.630|ES| 19:1 94:1 102:1 103:1 214:1 303:1 304:1 411:1 836:1 949:1 2460:1 2463:1 2464:1
-1 	|BT| (S (NP (JJ Branched-chain) (NN amino) (NN acid) (-LRB- -LRB-) (NN BCAA) (-RRB- -RRB-)) (, ,) (S (VP (VB improve) (NP (NN insulin) (NN resistance)))) (, ,) (VP (VBD inhibited) (NP (NP (JJ obesity-related) (NN colon) (NN carcinogenesis) (JJ rodent) (NN model)) (, ,) (S (ADVP (RB also)) (VP (VBD reduced) (NP (NN incidence) (JJ hepatocellular) (NN carcinoma) (JJ obese) (NN patient) (NN liver) (NN cirrhosis))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 50:M01.643 104:C04.557.470.200.025.255 122:C14.280.383 357:C06.552.630 434:E05.318.308.985.525.375 514:B01.050.150.900.649.865 564:C18.654.726.500 639:D12.125.070 678:C18.452.394.968.500|ES| 2:1 5:1 10:1 14:1 19:1 72:1 113:1 120:1 207:1 303:1 304:1 365:1 452:1 836:1 1094:1 1199:1 1275:1 1511:1 2173:1 2189:1 2360:1 2364:1 2465:1 2466:1 2467:1 2468:1
-1 	|BT| (S (NP (JJ Bromelain-containing) (NN food) (CC and/or) (NN bromelain)) (VP (MD may) (VP (VB represent) (NP (JJ good) (NN candidate) (JJ colorectal) (NN cancer) (NN chemoprevention))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 253:E02.319.162 679:D08.811.277.656.262.500.096 680:G07.203.300|ES| 17:1 18:1 19:1 149:1 491:1 799:1 870:1 1243:1 1318:1 2469:1 2470:1 2471:1
-1 	|BT| (S (NP (NP (NNP Brucine)) (, ,) (NP (NN alkaloid) (NN seed))) (VP (VBZ Strychnos) (NP (JJ nux-vomica) (NNP Linn)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 627:A18.024.500.750 628:B01.650.940.800.575.100.638.750.500 631:D03.132 681:G04.299.283 682:D12.776.260.103.625|ES| 2:1 19:1 31:1 63:1 94:1 98:1 104:1 185:1 303:1 304:1 383:1 514:1 806:1 2315:1 2320:1 2321:1 2322:1 2323:1 2472:1 2473:1 2474:1
-1 	|BT| (S (NP (NP (NNP Celecoxib)) (, ,) (NP (NP (JJ selective) (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (NP (NN inhibitor)) (, ,)) (NP (JJ effective) (JJ chemopreventive) (NN colon) (NN cancer) (JJ nonsteoroidal) (JJ antiinflammatory) (NN drug)) (VP (VBD approved) (NP (NP (NNP FDA) (JJ adjuvant) (NN therapy) (NN patient)) (JJ familial) (JJ adenomatous) (NN polyposis)))) |ET| |BS|3:C04.557.470.035.215.100 50:M01.643 52:E02 349:D27.505.519.389.310.500 633:I01.409.418.750.600.650.760 683:D27.505.519.389.310 684:D02.065.884.247 685:D27.505.696.477.067 686:D27.505.954.158 687:D26.650.064|ES| 2:1 10:1 14:1 18:1 19:1 57:1 58:1 61:1 76:1 113:1 120:1 130:1 191:1 380:1 854:1 1639:1 1749:1 1946:1 2343:1 2475:1 2476:1 2477:1 2478:1 2479:1
-1 	|BT| (S (NP (NNP Coffee)) (VP (VBZ reduces) (NP (NP (NN liver) (NN damage) (NN rat) (NN model) (NN steatohepatitis)) (: :) (NP (VBG underlying) (NN mechanism) (NN role) (NNS polyphenols) (NNS melanoidins))))) |ET| |BS|15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249|ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1
-1 	|BT| (S (NP (NN Colon) (NN cancer) (NN cell) (JJ treated) (NNS SDs)) (VP (VBD exhibited) (NP (VBN reduced) (NN Wnt) (JJ transcriptional) (NN activity)) (, ,) (VP (ADVP (RB well)) (VBN reduced)) (NP (JJ nuclear) (NN beta-catenin) (NN localization) (JJ subsequent) (NN reduction) (NN active-beta-catenin) (NN level)))) |ET| |BS|23:D12.776.091.249 41:A11 52:E02 175:J01.897.280.500.269 209:G02.111.087.847|ES| 2:1 18:1 19:1 60:1 94:1 249:1 370:1 399:1 452:1 559:1 609:1 787:1 877:1 1099:1 1256:1 1319:1 2482:1 2483:1 2484:1 2485:1
-1 	|BT| (S (NP (NN Combination) (NN aspirin) (NN sorafenib)) (VP (MD may) (NP (JJ effective) (NN regimen) (NN treat) (NN HCC) (NN colon) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255 532:E02.183 670:D02.455.426.559.389.657.410.595.176|ES| 18:1 19:1 113:1 441:1 491:1 1090:1 1639:1 1881:1 2063:1 2486:1 2487:1
-1 	|BT| (S (NP (NP (JJ Combined) (NN treatment) (NN EPLE) (NN 5-fluorouracil)) (, ,) (NP (JJ first-line) (NN chemotherapy) (NN CRC) (NN patient)) (, ,)) (VP (VBD achieved) (NP (JJ synergistic) (NN effect)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 151:E02.319 560:D03.383.742.698.875.404 618:E02.186|ES| 2:1 19:1 75:1 120:1 245:1 495:1 546:1 2012:1 2307:1 2488:1 2489:1 2490:1 2491:1
-1 	|BT| (S (VP (VBG Combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam) (NN treat) (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1
-1 	|BT| (S (NP (NN Compound) (NN Astragalus)) (NP (FW Salvia) (FW miltiorrhiza) (NN extract)) (VP (VBZ suppresses) (NP (NP (JJ hepatocellular) (NN carcinoma) (NN progression)) (VP (VBG inhibiting) (NP (NN fibrosis) (NN PAI-1) (NN mRNA) (NN transcription)))))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 111:D13.444.735.544 122:C14.280.383 209:G02.111.087.847 688:B01.650.940.800.575.100.401.087 689:A02.835.232.043.300.710.780 690:D12.644.861.695.500 691:C23.550.355|ES| 19:1 48:1 303:1 304:1 325:1 487:1 686:1 880:1 949:1 2492:1 2493:1 2494:1 2495:1 2496:1 2497:1
-1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (ADVP (RB Collectively)) (, ,) (VP (VBP result) (VP (VBP suggest) (SBAR (S (NP (NN curcumin)) (VP (VBZ potentiates) (NP (NP (JJ antitumor) (NN effect) (NN radiation) (NN therapy)) (JJ colorectal) (NN cancer) (VBG suppressing) (NP (NN NF-kappaB) (JJ NF-kappaB-regulated) (NN gene) (NN product))) (, ,) (NP (VBG leading) (NN inhibition) (NN proliferation) (NN angiogenesis))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 43:F01.145.544 52:E02 86:D01.268.556.435 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 693:G01.750.745|ES| 2:1 9:1 17:1 18:1 19:1 75:1 101:1 103:1 104:1 130:1 299:1 639:1 675:1 714:1 796:1 1872:1 1882:1 2244:1 2250:1 2498:1 2499:1 2500:1 2501:1 2502:1
-1 	|BT| (S (NP (NN CONCLUSION) (: :)) (PP (IN In) (NP (NN summary))) (, ,) (S (VP (VBG finding) (VP (VB provide) (NP (NP (JJ preclinical) (NN evidence)) (VP (VBG supporting) (NP (NN evaluation) (NN agent) (NN DMAPT) (NN gemcitabine) (NN prevention) (NN treatment) (JJ pancreatic) (NN cancer)))))))) |ET| |BS|52:E02 225:E05.337|ES| 2:1 18:1 19:1 38:1 104:1 244:1 467:1 490:1 546:1 711:1 728:1 927:1 1472:1 1474:1 1494:1 1882:1 2503:1 2504:1 2505:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (SBAR (S (NP (NN coffee) (NN consumption)) (VP (VBZ protects) (SBAR (S (NP (NN liver) (NN damage)) (VP (VBD caused) (NP (JJ high-fat) (NN diet))))))))))) |ET| |BS|242:A03.620 652:D20.215.784.249 694:G07.203.650.240.267|ES| 19:1 104:1 502:1 658:1 793:1 836:1 1848:1 1863:1 1882:1 2191:1 2386:1 2387:1 2506:1 2507:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (NP (NP (JJ Regular) (NN aspirin) (NN use) (NN diagnosis) (JJ colorectal) (NN cancer)) (VP (VBD associated) (NP (NP (JJR lower) (NN risk) (JJ colorectal) (JJ cancer-specific) (JJ overall) (NN mortality)) (, ,) (PP (ADVP (RB especially)) (IN among) (NP (JJ individual) (NN tumor)))) (S (VP (VBP overexpress) (NP (NN COX-2))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 61:E05.318.740.600.800 263:E01 493:M01 670:D02.455.426.559.389.657.410.595.176 695:E05.318.308.985.550 696:V02.270.500|ES| 2:1 7:1 17:1 18:1 19:1 76:1 104:1 117:1 169:1 171:1 345:1 1037:1 1372:1 1659:1 1882:1 2487:1 2508:1 2509:1 2510:1 2511:1 2512:1 2513:1
-1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (DT The) (JJ present) (NN work)) (VP (VBZ provides) (NP (NP (JJ novel) (NNS data)) (PP (VBG concerning) (NP (JJ preventive) (NN action) (NN glycerol) (NN development) (NN liver) (NN cancer)))))) (VP (VBZ represents) (NP (ADJP (RB economically) (JJ feasible)) (NN intervention) (NN treat) (JJ high-risk) (NN individual))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 61:E05.318.740.600.800 259:D12.776.395.240.150.500 445:I03.946 493:M01 697:D02.033.800.421 698:I01.261|ES| 18:1 19:1 35:1 104:1 106:1 691:1 793:1 815:1 836:1 891:1 1090:1 1307:1 1546:1 1645:1 1882:1 1883:1 2013:1 2512:1 2514:1 2515:1 2516:1 2517:1 2518:1
-1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (NP (DT These) (VBP result) (NP (VBN suggested) (NN TFA) (VBD protected) (ADJP (NN mouse) (JJ CCl4-induced) (ADJP (NN liver) (NN injury) (JJ antioxidant)) (NN stress) (JJ antiinflammatory)) (NN effect)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 242:A03.620 686:D27.505.954.158 699:D02.241.081.018.285.500 700:D27.505.519.217|ES| 19:1 52:1 75:1 101:1 104:1 792:1 836:1 925:1 1882:1 2413:1 2416:1 2477:1 2519:1 2520:1 2521:1 2522:1
-1 	|BT| (FRAG (NP (NN CONCLUSION)) (: :) (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NN evidence) (NN saffron)) (VP (VBZ exerts) (NP (JJ significant) (JJ chemopreventive) (NN effect) (NN liver) (NN cancer) (NN inhibition) (NN cell) (NN proliferation) (NN induction) (NN apoptosis)))))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 183:G04.299.233.750 624:D27.505.696.706.018 701:B01.650.940.800.575.100.549.500|ES| 18:1 19:1 38:1 75:1 89:1 94:1 103:1 104:1 131:1 135:1 299:1 736:1 807:1 815:1 836:1 1882:1 1946:1 1977:1 2523:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (NP (NNP Aliskiren)) (VP (VBZ attenuates) (NP (NN steatohepatitis) (NN fibrosis) (NN mouse) (NN fed) (NN MCD) (NN diet)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 691:C23.550.355|ES| 19:1 52:1 104:1 239:1 949:1 1791:1 2191:1 2422:1 2423:1 2426:1 2524:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Magnolol) (NNS pretreatments)) (VP (VBP prevent) (S (NP (JJ UVB-induced) (NN skin) (NN cancer) (NN development)) (VP (VBG enhancing) (NP (NN apoptosis)) (, ,) (S (VP (VBG causing) (NP (NN cell) (NN cycle) (NN arrest) (NN G2/M) (NN phase)))))) (, ,) (S (VP (VBG affecting) (NP (JJ various) (NN signaling) (NN pathway))))))) |ET| |BS|39:G04.299.139.160 126:G02.111.087.800 702:G04.299.134.109.750|ES| 2:1 18:1 19:1 35:1 89:1 94:1 104:1 195:1 239:1 383:1 601:1 602:1 733:1 1096:1 1491:1 2312:1 2319:1 2525:1 2526:1 2527:1 2528:1 2529:1 2530:1
-1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NN Silibinin) (NN target) (NN beta-catenin) (NN IGF-1Rbeta) (NN pathway) (JJ chemopreventive) (NN efficacy) (JJ azoxymethane-induced) (NN colon) (NN carcinogenesis) (NN A/J) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 581:D12.644.276.937|ES| 19:1 52:1 60:1 104:1 113:1 160:1 207:1 239:1 383:1 1946:1 2304:1 2531:1 2532:1 2533:1 2534:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (PP (IN Since) (NP (NN lymph) (NN node) (NN involvement) (JJ important) (JJ prognostic) (NN factor) (NN breast) (NN cancer) (NN patient))) (, ,) (NP (JJ antimetastatic) (NN activity) (NN alpha-mangostin)) (VP (VBD detected) (NP (NP (JJ mammary) (NN cancer)) (VP (VBG carrying) (NP (NN p53) (NN mutation) (JJ present) (NN study)))) (VP (MD may) (NP (JJ specific) (JJ clinical) (NN application))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 18:G05.365.590 50:M01.643 247:G01.374.676.530 703:A10.549.400|ES| 2:1 12:1 18:1 19:1 23:1 34:1 84:1 104:1 120:1 131:1 165:1 185:1 239:1 399:1 491:1 540:1 636:1 850:1 884:1 902:1 1007:1 1307:1 2245:1 2246:1 2248:1 2535:1 2536:1 2537:1
-1 	|BT| (S (NP (NNS CONCLUSIONS) (: :)) (VP (VBN Taken) (ADVP (RB together)) (, ,) (S (VP (VBG finding) (VP (VB identify) (S (NP (NN mechanism) (NN ABT-100) (NN function)) (VP (VBP show) (NP (NP (NN efficacy) (NN ABT-100) (JJ chemopreventive) (NN agent)) (NP (JJ hepatocellular) (NN carcinoma)))))))))) |ET| |BS|104:C04.557.470.200.025.255 375:Z01.639.100|ES| 2:1 19:1 33:1 104:1 162:1 239:1 303:1 304:1 429:1 728:1 832:1 927:1 1537:1 1538:1 1946:1 2304:1 2538:1
-1 	|BT| (FRAG (NP (NNS CONCLUSIONS) (: :)) (PP (DT These) (S (VP (VBG finding) (S (VP (VBP suggest) (NP (NP (NN MPT0E028) (NN combination) (NN sorafenib) (JJ significant) (JJ anti-hepatocellular) (NN carcinoma) (NN activity) (JJ preclinical) (NN model)) (, ,) (S (ADVP (RB potentially)) (VP (VBG suggesting) (SBAR (S (NP (JJ novel) (JJ therapeutic) (NN strategy) (NN patient)) (VP (VBD advanced) (NP (JJ hepatocellular) (NN carcinoma)))))))))))))) |ET| |BS|50:M01.643 52:E02 104:C04.557.470.200.025.255 259:D12.776.395.240.150.500|ES| 2:1 19:1 72:1 104:1 120:1 135:1 239:1 303:1 304:1 399:1 530:1 541:1 773:1 792:1 796:1 891:1 927:1 997:1 1009:1 1114:1 1494:1 2063:1 2539:1 2540:1
-1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT This) (NN study)) (VP (VBZ demonstrates) (NP (JJ synergistic) (NN antitumor) (NN activity) (NN combination) (NN dovitinib) (NN oxaliplatin) (NN colon) (NN cancer) (JJ different) (NN RAS-RAF) (NN status))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550|ES| 18:1 19:1 104:1 113:1 131:1 239:1 399:1 414:1 416:1 530:1 807:1 2012:1 2244:1 2541:1 2542:1 2543:1 2544:1
-1 	|BT| (NP (NP (NP (NN Connexin) (CD 32) (NN luteolin) (NN play) (JJ protective) (NN role)) (JJ non-alcoholic) (NN steatohepatitis) (NN development) (JJ related) (NN hepatocarcinogenesis) (NN rat))) |ET| |BS|15:F01.829.316.616 79:I03.450.642.693 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 509:C06.552.241.519 704:D03.383.663.283.266.450.260.555|ES| 19:1 31:1 35:1 238:1 419:1 493:1 849:1 900:1 1791:1 2069:1 2545:1 2546:1 2547:1
-1 	|BT| (S (NP (NN Cyclooxygenase-2) (NN inhibitor)) (VP (VBP down-regulate) (NP (NN osteopontin) (NN Nr4A2-new) (JJ therapeutic) (NN target) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360|ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1
-1 	|BT| (S (NP (NN Cytochrome) (NN P450) (NN 1A2)) (VP (VBZ Metabolizes) (S (NP (NN 17beta-Estradiol)) (VP (VB Suppress) (NP (JJ Hepatocellular) (NN Carcinoma)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 705:D08.244.453.040.443 706:D04.808.365.415.248|ES| 19:1 1241:1 2151:1 2548:1 2549:1 2550:1 2551:1 2552:1 2553:1
-1 	|BT| (S (NP (NP (NNS Data)) (VP (VBN obtained))) (VP (VBP suggest) (S (NP (NN contribution) (NN SphK/S1P) (NN system)) (NP (JJ related) (NN signaling) (NN pathway) (JJ protective) (NN effect) (NN melatonin) (NN hepatocarcinogenesis))))) |ET| |BS|126:G02.111.087.800 707:D03.438.473.914.481|ES| 19:1 75:1 195:1 383:1 419:1 493:1 593:1 796:1 900:1 1224:1 1360:1 2554:1 2555:1 2556:1
-1 	|BT| (NP (NP (NP (JJ Decorin-mediated) (NN inhibition) (JJ colorectal) (NN cancer) (NN growth) (NN migration)) (NP (VBN associated) (NN E-cadherin) (NN vitro) (NN mouse)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 43:F01.145.544 45:G07.700.320.249 613:D12.776.395.550.200.200 708:D12.776.395.650.750.625|ES| 17:1 18:1 19:1 52:1 102:1 103:1 169:1 216:1 514:1 2267:1 2557:1
-1 	|BT| (S (PP (IN Despite) (NP (JJ recent) (JJ therapeutic) (NN advance))) (, ,) (NP (NP (NN response) (NN rate) (NN chemotherapy) (NN patient)) (JJ metastatic) (NN colon) (NN cancer)) (VP (VBP remain) (NP (NP (NP (QP (RB approximately) (CD 50)) (NN %)) (NP (NN fluoropyrimidine))) (, ,) (NP (NN 5-fluorouracil) (-LRB- -LRB-) (NN 5-FU) (-RRB- -RRB-))) (, ,) (S (VP (VBG continuing) (VP (VB serve) (NP (NN foundation) (JJ chemotherapeutic) (NN agent) (NN treatment) (NN disease))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 50:M01.643 52:E02 113:C04.697.650 151:E02.319 288:C23.550.288 560:D03.383.742.698.875.404 660:D27.505.954.248 709:N03.219.483.311|ES| 2:1 10:1 14:1 18:1 19:1 41:1 113:1 120:1 337:1 368:1 369:1 494:1 495:1 532:1 541:1 546:1 550:1 659:1 728:1 998:1 1762:1 1843:1 2181:1 2307:1 2308:1 2558:1 2559:1 2560:1 2561:1
-1 	|BT| (S (NP (NP (JJ Dietary) (NN intake) (NN pterostilbene)) (, ,) (NP (NN constituent) (NN blueberry)) (, ,)) (VP (VBZ inhibits) (NP (NN beta-catenin/p65) (JJ downstream) (NN signaling) (NN pathway) (NN colon) (NN carcinogenesis) (NN rat)))) |ET| |BS|23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 595:G07.203.650.240 710:B01.650.940.800.575.100.343.774.249|ES| 2:1 19:1 113:1 195:1 207:1 383:1 560:1 615:1 849:1 2428:1 2457:1 2562:1 2563:1 2564:1 2565:1
-1 	|BT| (S (NP (JJ Dietary) (NN lycopene) (NN tomato) (NN extract) (NN supplementation)) (VP (VBP inhibit) (NP (JJ nonalcoholic) (JJ steatohepatitis-promoted) (NN hepatocarcinogenesis) (NN rat)))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 509:C06.552.241.519 595:G07.203.650.240|ES| 19:1 849:1 900:1 1097:1 1370:1 1796:1 2496:1 2562:1 2566:1 2567:1 2568:1
-1 	|BT| (S (S (NP (JJ Diethylnitrosamine-induced) (NN hepatocarcinogenesis)) (VP (VBD suppressed) (NP (NN lecithin)))) (: :) (S (NP (NN retinol) (JJ acyltransferase-deficient) (NN mouse)) (ADVP (RB primarily)) (NP (NP (JJ retinoid) (NN action)) (NP (ADVP (RB immediately)) (NP (NN carcinogen) (NN administration)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 279:D27.888.569.100 554:D02.654.442.200 711:D02.455.326.271.665.202.495|ES| 19:1 52:1 104:1 307:1 900:1 1970:1 2013:1 2125:1 2569:1 2570:1 2571:1 2572:1 2573:1 2574:1 2575:1
-1 	|BT| (S (VP (NP (NNP Digital)) (VBG karyotyping) (VP (VBZ identifies) (NP (NN thymidylate) (NN synthase) (NN amplification) (NN mechanism) (NN resistance) (NN 5-fluorouracil) (JJ metastatic) (JJ colorectal) (NN cancer) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430|ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1
-1 	|BT| (S (NP (NNP Diosmin)) (VP (VBZ abrogates) (VP (ADVP (RB chemically)) (VBN induced) (NN hepatocarcinogenesis) (PP (IN via) (NP (NP (NN alleviation) (JJ oxidative) (NN stress)) (, ,) (NP (JJ hyperproliferative) (JJ inflammatory) (NN marker) (JJ murine) (NN model))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 158:D23.101 715:D03.383.663.283.266.450.260.222 716:G03.495.710|ES| 2:1 19:1 72:1 412:1 534:1 596:1 627:1 900:1 2430:1 2522:1 2579:1 2580:1 2581:1 2582:1 2583:1 2584:1
-1 	|BT| (S (NP (NP (NN DNA) (NN microarray) (NN analysis)) (VP (VBN used))) (VP (VBP analyze) (NP (NP (JJ transcriptional) (NN profile) (NN HCT116) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBN treated) (NP (NP (NP (NN 5-fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-))) (NN oxaliplatin) (VBN selected) (NN resistance) (NN agent)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 198:D13.444.308 209:G02.111.087.847 560:D03.383.742.698.875.404 717:A11.251.210.190.380 718:E05.588.570|ES| 10:1 14:1 17:1 18:1 19:1 94:1 476:1 559:1 566:1 661:1 666:1 728:1 913:1 1094:1 1099:1 1711:1 2307:1 2308:1 2543:1 2585:1 2586:1
-1 	|BT| (S (NP (NN Embelin)) (VP (VBZ inhibits) (NP (NP (NN chemical) (JJ carcinogen-induced) (NN colon) (NN carcinogenesis)) (, ,) (NP (NP (NN effect)) (ADJP (RB partially) (JJ dependent)) (NN presence) (JJ functional) (NN PPARgamma)) (, ,) (NP (NP (VBG indicating) (NN PPARgamma) (JJ necessary) (NN signaling) (NN pathway)) (VBN involved) (NN antitumor) (NN activity) (JJ normal) (NN organism))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 69:G02.111.087.800 122:C14.280.383 126:G02.111.087.800 279:D27.888.569.100 719:D12.776.826.239.588|ES| 2:1 19:1 75:1 113:1 118:1 195:1 207:1 321:1 346:1 383:1 399:1 415:1 615:1 774:1 1351:1 2124:1 2236:1 2244:1 2421:1 2587:1 2588:1 2589:1 2590:1
-1 	|BT| (S (NP (JJ Epidemiological) (NN evidence)) (VP (VBZ suggests) (S (NP (NN vitamin) (NN D)) (VP (MD may) (VP (VB play) (NP (NP (NN role)) (VP (VBG inhibiting) (NP (NN development) (NN colon) (NN prostate) (NN cancer))))))))) |ET| |BS|15:F01.829.316.616 46:A03.556.124.526.356 79:I03.450.642.693 122:C14.280.383 651:H02.403.720.500 720:D04.808.247.222.474 721:D04.808.812.768|ES| 18:1 19:1 31:1 35:1 38:1 77:1 113:1 238:1 331:1 491:1 880:1 2384:1 2591:1 2592:1
-1 	|BT| (S (NP (JJ Epidemiological) (NN study)) (VP (VBP indicate) (NP (JJ adequate) (JJ dietary) (NN folate) (JJ protective) (NN colon) (NN cancer)) (, ,) (SBAR (IN although) (S (NP (NN mechanism)) (VP (VBP remain) (ADJP (RB largely) (JJ elusive))))))) |ET| |BS|224:D03.438.733.631.400 595:G07.203.650.240 722:E05.318.760.500|ES| 2:1 18:1 19:1 113:1 131:1 162:1 493:1 777:1 778:1 1479:1 1592:1 2181:1 2384:1 2593:1 2594:1 2595:1
-1 	|BT| (S (NP (NNP Erlotinib)) (ADVP (RB also)) (VP (VBD decreased) (NP (NN hepatocyte) (NN proliferation) (NN liver) (NN injury)))) |ET| |BS|242:A03.620 262:A11.436.348|ES| 5:1 19:1 202:1 299:1 836:1 1909:1 2416:1 2596:1
-1 	|BT| (S (NP (NN ESE-1) (: /) (NN EGR-1) (NN pathway)) (VP (VBP play) (NP (NN role)) (NP (ADJP (JJ tolfenamic) (JJ acid-induced)) (NP (NN apoptosis) (JJ colorectal) (NN cancer) (NN cell))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 39:G04.299.139.160 41:A11 79:I03.450.642.693|ES| 17:1 18:1 19:1 31:1 89:1 94:1 238:1 383:1 2597:1 2598:1 2599:1
-1 	|BT| (NP (NP (NP (NN Evaluation) (JJ chemopreventive) (NN effect)) (NP (NNP Fumaria) (NN indica) (NN N-nitrosodiethylamine) (JJ CCl4-induced) (JJ hepatocellular) (NN carcinoma) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 225:E05.337 554:D02.654.442.200 624:D27.505.696.706.018 723:B01.050.150.900.649.865.635.505.700.900 724:B01.650.940.800.575.100.443.750|ES| 19:1 75:1 303:1 304:1 849:1 1208:1 1946:1 2520:1 2600:1 2601:1 2602:1 2603:1
-1 	|BT| (NP (NP (NP (NN Exenatide)) (PRN (-LRB- -LRB-) (NP (NN Ex-4)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ potent) (NN diabetes) (NN drug)) (VP (VBG targeting) (NP (NP (JJ glucagon-like) (NN peptide-1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN GLP-1R)) (-RRB- -RRB-))))) (, ,) (NP (NP (JJ protective) (JJ non-alcoholic) (NN fatty) (NN liver) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN NAFLD)) (-RRB- -RRB-)))) |ET| |BS|369:E02.319.300 577:C06.552.241.519 725:D12.776.543.750.100.021.500 726:C18.452.394.750|ES| 2:1 10:1 14:1 19:1 22:1 186:1 191:1 493:1 616:1 836:1 998:1 2009:1 2069:1 2070:1 2604:1 2605:1 2606:1 2607:1 2608:1 2609:1
-1 	|BT| (SINV (ADVP (RB Furthermore)) (, ,) (NP (NN exposure) (JJ colorectal) (NN cancer) (NN cell) (JJ anti-periostin) (NN antibody)) (VP (VBZ activates) (NP (NN apoptosis))) (VP (VBZ potentiates) (NP (NN effect) (NN 5-fluorouracil) (NN chemotherapy)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 151:E02.319 560:D03.383.742.698.875.404 727:D12.776.124.486.485.114.071|ES| 2:1 17:1 18:1 19:1 75:1 89:1 94:1 301:1 334:1 495:1 1953:1 2307:1 2499:1 2610:1 2611:1
-1 	|BT| (S (NP (NNP Garcinol)) (VP (VBZ suppresses) (NP (JJ inflammation-associated) (NN colon) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 53:C06.405.205.265|ES| 19:1 52:1 113:1 207:1 686:1 1849:1 2612:1
-1 	|BT| (S (NP (JJ Garlic) (NN oil)) (VP (VBD attenuated) (NP (NP (JJ nitrosodiethylamine-induced) (NN hepatocarcinogenesis)) (VP (VBG modulating) (NP (JJ metabolic) (NN activation) (NN detoxification) (NN enzyme)))))) |ET| |BS|554:D02.654.442.200 728:G03.495.244.224 729:G03.495.244.450 730:D08.811|ES| 19:1 225:1 808:1 900:1 2006:1 2388:1 2435:1 2613:1 2614:1 2615:1 2616:1
-1 	|BT| (NP (NP (NP (NNP Gemcitabine)) (, ,) (NP (JJ current) (JJ standard-of-care) (NN chemotherapy) (JJ pancreatic) (NN cancer)) (, ,) (NP (JJ limited) (JJ clinical) (NN benefit)))) |ET| |BS|151:E02.319|ES| 2:1 18:1 19:1 84:1 175:1 467:1 495:1 2131:1 2617:1 2618:1 2619:1
-1 	|BT| (S (NP (NNS Glucans) (JJ edible) (NN mushroom) (NN Pleurotus) (NN pulmonarius)) (VP (VBP inhibit) (NP (JJ colitis-associated) (NN colon) (NN carcinogenesis) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 53:C06.405.205.265 122:C14.280.383 731:B01.300.179.100.650 732:D05.750.078.562 733:B01.300.179.100|ES| 19:1 52:1 113:1 207:1 410:1 1370:1 2620:1 2621:1 2622:1 2623:1 2624:1
-1 	|BT| (NP (NP (NP (JJ Glycyrrhizic) (NN Acid)) (NP (VBN used) (NN treat) (JJ chronic) (NN hepatitis))) (, ,) (S (VP (VBG inhibiting) (NP (NN penetration) (NN hepatitis) (NN A) (NN virus) (NNS hepatocytes))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 122:C14.280.383 262:A11.436.348 734:D02.455.849.919.530.466 735:B04.450.420.410 736:C06.552.380.350|ES| 2:1 19:1 69:1 476:1 880:1 894:1 1090:1 1422:1 1790:1 2048:1 2625:1 2626:1 2627:1
-1 	|BT| (S (NP (JJ Great) (NN interest)) (VP (VBD focused) (NP (NN chemoprevention) (JJ colonic) (NN carcinogenesis) (JJ oral) (NN administration)) (NP (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (NN administration)) (VP (ADVP (RB reportedly)) (VBZ reduces) (NP (NN incidence) (NN colon) (NN cancer) (NN animal) (NN experiment))))) |ET| |BS|33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 253:E02.319.162 434:E05.318.308.985.525.375 737:D04.808.105.225.272.962 738:E05.017 739:E02.319.267.100|ES| 10:1 14:1 18:1 19:1 46:1 113:1 142:1 207:1 677:1 870:1 1051:1 1275:1 1511:1 2310:1 2311:1 2575:1 2628:1 2629:1 2630:1 2631:1 2632:1
-1 	|BT| (SINV (ADVP (RB Here)) (VP (VBN aimed)) (VP (VBP determine) (NP (NP (NN mechanism) (NN action) (NN DHEA)) (, ,) (NP (NP (NN comparison) (NN vitamin) (NN E)) (, ,) (NP (JJ chemically-induced) (JJ hepatocellular) (NN carcinoma) (NN model) (NN rat)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 740:D04.808.054.079.429.625 741:D03.383.663.283.909 742:G03.787|ES| 2:1 19:1 72:1 74:1 162:1 303:1 304:1 400:1 844:1 849:1 2013:1 2085:1 2233:1 2591:1 2633:1 2634:1
-1 	|BT| (S (NP (ADVP (RB Herein)) (, ,) (JJ first) (NN time)) (, ,) (VP (VBP investigate) (NP (FW vivo) (NN efficacy) (NN silibinin) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN A/J) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 322:G01.910|ES| 2:1 19:1 52:1 78:1 113:1 378:1 428:1 459:1 816:1 1081:1 2304:1 2533:1 2534:1 2635:1
-1 	|BT| (NP (NP (ADVP (RB However)) (, ,) (NP (NN investigation) (JJ protective) (NN effect) (NN betaine) (NN hepatocarcinogenesis)))) |ET| |BS|225:E05.337 743:D02.092.877.883.077|ES| 2:1 19:1 75:1 433:1 493:1 900:1 1497:1 2636:1
-1 	|BT| (S (NP (NN HTHQ)) (ADVP (RB also)) (VP (VBD inhibited) (NP (NP (NP (JJ 2-amino-1-methyl-6-phenylimidazo) (-LRB- -LSB-) (JJ 4,5-b) (-RRB- -RSB-) (NN pyridine)) (PRN (-LRB- -LRB-) (NP (NN PhIP)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN carcinogenesis) (CD two) (NN stage) (NN colon) (NN carcinogenesis) (NN model)) (S (VP (VBG using) (NP (NP (NP (NN 1,2-dimethylhydrazine)) (PRN (-LRB- -LRB-) (NP (NN DMH)) (-RRB- -RRB-))) (NN initiator))))))) |ET| |BS|33:C04.697.098 46:A03.556.124.526.356 122:C14.280.383 744:D03.383.725|ES| 5:1 10:1 14:1 19:1 72:1 113:1 207:1 350:1 365:1 409:1 933:1 1129:1 1373:1 1378:1 2637:1 2638:1 2639:1 2640:1 2641:1 2642:1 2643:1 2644:1
-1 	|BT| (S (NP (JJ Hyperactive) (NN EGFR) (NN signaling) (NN Stat3) (NN Jak-Stat3) (NN activity)) (ADVP (RB together)) (VP (VBP promote) (SBAR (S (NP (NP (JJ ovarian) (NN cancer) (NN progression) (NN cisplatin) (NN resistance)) (ADVP (RB therefore))) (VP (VBP represent) (NP (NP (NN target)) (VP (VBG preventing) (NP (NN development) (NN cisplatin) (NN resistance) (JJ recurrent) (NN disease) (NN cisplatin) (NN therapy) (JJ ovarian) (NN cancer))))))))) |ET| |BS|16:C23.550.291.656 52:E02 69:G02.111.087.800 82:D12.644.360.024.342.300 288:C23.550.288 496:C23.550.291.937 498:D01.210.375 745:C10.597.350.350|ES| 18:1 19:1 35:1 48:1 130:1 160:1 187:1 195:1 218:1 399:1 679:1 799:1 998:1 1094:1 1538:1 1753:1 1761:1 1763:1 1937:1 2645:1 2646:1 2647:1
-1 	|BT| (FRAG (NP (NP (JJ Immunohistochemical) (NN analysis)) (JJ late) (NN stage) (NN tumor) (NN promotion) (NN oxfendazole) (NN rat) (NN hepatocarcinogenesis) (NN model))) |ET| |BS|8:C04 38:Z01.058.290.120.180 40:Z01.542.248.700 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700|ES| 7:1 19:1 72:1 661:1 849:1 900:1 1129:1 2337:1 2648:1 2649:1 2650:1
-1 	|BT| (S (ADVP (RB Importantly)) (, ,) (NP (NN cotreatment) (JJ low) (NNS dos) (NP (NP (NNS oligoamines) (NN DNA) (NN methyltransferase) (NN inhibitor)) (ADVP (RB highly)))) (VP (VBZ induces) (SBAR (S (NP (NN reexpression)) (ADVP (RB aberrantly)) (VP (VBD silenced) (SBAR (S (NP (NN SFRP2) (NN gene)) (VP (VBP result) (NP (NP (JJ significant) (NN inhibition) (NN growth)) (VBN established) (NN tumor) (JJ human) (NN colon) (NN tumor) (NN model)) (FW vivo))))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 43:F01.145.544 45:G07.700.320.249 51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 618:E02.186 746:D08.811.150.240|ES| 2:1 7:1 9:1 19:1 36:1 72:1 101:1 102:1 103:1 113:1 135:1 214:1 378:1 380:1 531:1 626:1 666:1 2651:1 2652:1 2653:1 2654:1 2655:1 2656:1 2657:1 2658:1 2659:1 2660:1
-1 	|BT| (S (PP (IN In) (NP (CD 2012) (NN case) (NN report))) (, ,) (VP (VBN described) (NP (NP (NN breakthrough)) (VP (VBG finding) (NP (NP (CD two) (JJ advanced) (NNP HCC) (NN patient)) (, ,) (NP (S (NP (CD one)) (VP (VBD achieved) (SBAR (S (NP (JJ complete) (NN remission) (NN liver) (NN tumor)) (VP (VBD normalized) (NP (NP (NN alpha-fetoprotein) (NN level)) (, ,) (PP (IN along) (NP (JJ complete) (NN remission) (NN lung) (NN metastasis))))))))) (, ,) (NP (JJ concomitant) (NN use) (NN thalidomide) (NN cyproheptadine)))))))) |ET| |BS|50:M01.643 104:C04.557.470.200.025.255 113:C04.697.650 182:A04.411 275:C23.888 405:V03.100 406:V03.100 515:C04.588.274.623 747:D02.455.426.559.847.181.384.340 748:D12.776.124.790.106.092 749:D02.241.223.805.810.800|ES| 2:1 7:1 19:1 120:1 172:1 244:1 249:1 328:1 417:1 441:1 634:1 806:1 836:1 927:1 933:1 934:1 997:1 1010:1 1659:1 1681:1 2491:1 2661:1 2662:1 2663:1 2664:1 2665:1 2666:1 2667:1 2668:1
-1 	|BT| (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN alpha-mangostin)) (VP (MD may) (VP (VB chemopreventive) (NP (NP (NN benefit)) (CC and/or) (VP (VB prove) (NP (NP (JJ useful) (JJ adjuvant) (NN therapy)) (, ,) (NP (JJ complementary) (NN alternative) (NN medicine) (NN treatment) (NN breast) (NN cancer)))))))) |ET| |BS|52:E02 685:D27.505.696.477.067 687:D26.650.064 750:E02.190|ES| 2:1 18:1 19:1 23:1 130:1 149:1 244:1 468:1 491:1 546:1 1036:1 1946:1 2246:1 2327:1 2479:1 2619:1 2669:1 2670:1 2671:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NP (NN dioscin) (NN show) (JJ excellent) (JJ protective) (NN effect)) (JJ ethanol-induced) (NN liver) (NN injury)) (S (VP (VBG ameliorating) (NP (NP (JJ ethanol-induced) (JJ oxidative) (NN stress)) (, ,) (NP (JJ mitochondrial) (NN function)) (, ,)) (NP (NP (JJ inflammatory) (NP (NN cytokine)) (NN production)) (, ,) (NP (NN apoptosis) (NN liver) (NN steatosis)) (, ,))))) (VP (VBD developed) (NP (JJ new) (NN drug) (NN treatment) (JJ ethanol-induced) (NN liver) (NN injury) (NN future)))) |ET| |BS|39:G04.299.139.160 52:E02 67:D26 242:A03.620 354:I01.320 508:C06.552.241 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 716:G03.495.710 751:D02.033.375 752:D12.644.276.374 753:C06.552.241|ES| 2:1 19:1 33:1 75:1 89:1 191:1 244:1 429:1 493:1 546:1 712:1 836:1 1165:1 1190:1 1284:1 2004:1 2416:1 2430:1 2522:1 2583:1 2672:1 2673:1 2674:1 2675:1 2676:1 2677:1 2678:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN simvastatin)) (VP (VBD inhibited) (NP (NP (NN colon) (NN cancer) (NN development) (NN induction)) (NN apoptosis) (NN suppression) (NN angiogenesis)))) |ET| |BS|39:G04.299.139.160 122:C14.280.383 754:D02.455.426.559.847.638.400.900|ES| 2:1 18:1 19:1 35:1 89:1 113:1 244:1 365:1 736:1 1284:1 2453:1 2502:1 2679:1
-1 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (VP (VBD investigated) (SBAR (IN whether) (S (NP (NP (JJ ursodeoxycholic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN UDCA)) (-RRB- -RRB-))) (VP (VBP inhibit) (NP (NP (JJ colitis-related) (NN mouse) (NN colon) (NN carcinogenesis)) (VBN compared) (NN effect) (NN sulfasalazine))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 53:C06.405.205.265 122:C14.280.383 737:D04.808.105.225.272.962 755:D02.065.884.730|ES| 2:1 10:1 14:1 19:1 50:1 52:1 75:1 113:1 131:1 175:1 207:1 221:1 244:1 403:1 1275:1 1370:1 2630:1 2631:1 2680:1 2681:1
-1 	|BT| (FRAG (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBD investigated) (NP (JJ anticancer) (NN activity) (JJ tolfenamic) (NN acid) (JJ human) (JJ colorectal) (NN cancer) (NN cell)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 17:1 18:1 19:1 36:1 94:1 131:1 244:1 399:1 403:1 1275:1 1307:1 1880:1 2598:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBN shown) (NP (NP (JJ myrtenal) (, ,) (JJ natural) (NN monoterpene)) (, ,) (NP (VP (VBP act) (SBAR (S (NP (JJ antineoplastic) (NN agent) (NN diethylnitrosamine)) (VP (VBD induced) (NP (JJ phenobarbital) (VBN promoted) (NP (JJ experimental) (JJ hepatocellular) (NN carcinoma))))))))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 554:D02.654.442.200 660:D27.505.954.248 756:D03.383.742.698.253.650 757:C04.588.274.623.460 758:D02.455.849.575|ES| 2:1 19:1 131:1 237:1 244:1 246:1 263:1 303:1 304:1 412:1 728:1 1307:1 1912:1 1952:1 2333:1 2682:1 2683:1 2684:1 2685:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD demonstrated) (NP (NP (NN alantolactone)) (, ,) (NP (NN sesquiterpene) (NN lactone)) (, ,) (NP (NP (JJ potential) (NN activity) (JJ triple-negative) (NN breast) (NN cancer) (NN MDA-MB-231) (NN cell) (JJ suppressing) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (NN signaling) (NN pathway))))) |ET| |BS|41:A11 69:G02.111.087.800 160:C04.588.180.788 209:G02.111.087.847 250:E07.305.812 759:D02.092.471.683.152.660 760:Z01.107.084.900.600 761:G02.111.087.800 762:D02.455.849.765 763:Z01.542.248.540 764:D02.540|ES| 2:1 10:1 14:1 18:1 19:1 23:1 26:1 94:1 131:1 195:1 244:1 251:1 383:1 399:1 487:1 827:1 859:1 860:1 861:1 862:1 1175:1 1307:1 2250:1 2686:1 2687:1 2688:1 2689:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN examined) (NN effect) (NN pitavastatin) (: -) (NN drug)) (VP (VBD used) (S (NP (NN treatment) (NN hyperlipidemia)) (: -) (NP (NP (NN development) (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VP (VBN induced) (S (NP (NP (NN liver) (JJ preneoplastic) (NN lesion) (NN C57BL/KsJ-db/db)) (PRN (-LRB- -LRB-) (NP (NN db/db)) (-RRB- -RRB-))) (NP (JJ obese) (NN mouse))))))) |ET| |BS|52:E02 67:D26 242:A03.620 554:D02.654.442.200 593:B01.050.050.199.520.520.420 765:B01.050.150.900.649.865.635.505.500.550.530 766:C18.452.584.500.500|ES| 2:1 10:1 14:1 19:1 35:1 52:1 75:1 131:1 191:1 244:1 324:1 409:1 476:1 546:1 836:1 1131:1 1307:1 1438:1 1875:1 1952:1 2468:1 2690:1 2691:1 2692:1 2693:1 2694:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (NP (VBN shown) (NN diosmin)) (VP (VBZ attenuates) (SBAR (S (NP (NP (NN 2-AAF)) (VP (VBD induced) (NP (NP (NP (JJ hepatic) (NN toxicity) (JJ early) (NN tumor) (NN promotion) (NN marker)) (PRN (-LRB- -LRB-) (NP (NP (NN ODC)) (, ,) (NP (NN PCNA) (NN Ki67))) (-RRB- -RRB-))) (, ,) (NP (JJ chemopreventive) (NN efficacy) (NN DEN))))) (VP (VBD initiated) (NP (JJ 2-AAF) (VBN promoted) (NN hyper-proliferation) (NN hepatocarcinogenesis) (NNP Wistar) (NN rat))))))) |ET| |BS|376:D23.101.140 715:D03.383.663.283.266.450.260.222 723:B01.050.150.900.649.865.635.505.700.900 745:C10.597.350.350 767:D02.065.064.150 768:D12.776.660.740|ES| 2:1 7:1 10:1 14:1 19:1 131:1 237:1 244:1 412:1 534:1 838:1 849:1 900:1 1128:1 1307:1 1875:1 1900:1 1912:1 1946:1 2304:1 2337:1 2406:1 2423:1 2603:1 2695:1 2696:1 2697:1 2698:1 2699:1 2700:1
-1 	|BT| (NP (NP (PP (IN In) (NP (NN study))) (, ,) (NP (NP (NP (NN report) (NN effect) (NN resveratrol) (JJ early) (JJ advanced) (NN stage) (NN hepatocarcinogenesis) (NN model) (NN N-nitrosodiethylamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (: -) (VBN induced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (JJ male) (NNP Wistar) (NN rat)))) |ET| |BS|104:C04.557.470.200.025.255 554:D02.654.442.200 723:B01.050.150.900.649.865.635.505.700.900|ES| 2:1 10:1 14:1 19:1 72:1 75:1 131:1 244:1 303:1 304:1 409:1 417:1 441:1 849:1 900:1 997:1 1128:1 1129:1 1402:1 1712:1 1875:1 2602:1 2603:1
-1 	|BT| (S (NP (NN Inflexinol)) (VP (VBZ inhibits) (NP (NN colon) (NN cancer) (NN cell) (NN growth) (NN inhibition) (JJ nuclear) (NN factor-kappaB) (NN activity)) (PP (IN via) (NP (JJ direct) (NN interaction) (NN p50))))) |ET| |BS|41:A11 43:F01.145.544 45:G07.700.320.249 122:C14.280.383 210:D12.776.260.600|ES| 18:1 19:1 94:1 102:1 103:1 113:1 399:1 596:1 615:1 618:1 1256:1 1891:1 2377:1 2701:1 2702:1
-1 	|BT| (S (NP (NN Inhibition) (JJ retinoic) (NN acid) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (NN N-nitrosomorpholine) (NN expression) (NN myc) (NN oncogene) (NN protein) (JJ Sprague-Dawley) (NN rat)))) |ET| |BS|43:F01.145.544 584:D12.776.624.664 769:B01.050.150.900.649.865.635.505.700.750 770:D02.455.326.271.665.202.495.818.500|ES| 4:1 19:1 24:1 115:1 412:1 849:1 900:1 1275:1 2703:1 2704:1 2705:1 2706:1 2707:1
-1 	|BT| (NP (NP (NN Inhibition) (NP (NN c-Jun) (JJ NH2-terminal) (NN kinase) (NN switch)) (NN Smad3) (NN signaling) (NN oncogenesis) (NN tumor)) (: -) (NP (NN suppression) (NN rat) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 43:F01.145.544 69:G02.111.087.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 771:D08.811.913.696.620.682.700.567.374|ES| 19:1 195:1 303:1 304:1 470:1 849:1 1686:1 2453:1 2703:1 2708:1 2709:1 2710:1 2711:1 2712:1
